

# Maria Esposito

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4680988/publications.pdf>

Version: 2024-02-01

56  
papers

1,310  
citations

430442

18  
h-index

377514

34  
g-index

56  
all docs

56  
docs citations

56  
times ranked

1444  
citing authors

#	ARTICLE	IF	CITATIONS
1	A 48-week update of a multicentre real-life experience of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1146-1149.	1.1	19
2	Effects of TNF- $\alpha$ inhibition on pre-clinical enthesitis: observational study on 49 psoriatic patients. <i>Journal of Dermatological Treatment</i> , 2022, 33, 1703-1706.	1.1	6
3	Treatment adherence with diclofenac 3% gel among patients with multiple actinic keratoses: an integrated low-intensity intervention program versus standard-of-care. <i>Italian Journal of Dermatology and Venereology</i> , 2022, 157, .	0.1	2
4	A 52-week update of a multicentre real-life experience on effectiveness and safety of risankizumab in psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, .	1.3	12
5	Tildrakizumab for treatment of moderate to severe psoriasis: an expert opinion of efficacy, safety, and use in special populations. <i>Expert Opinion on Biological Therapy</i> , 2022, 22, 367-376.	1.4	9
6	Dimethyl Fumarate's Effectiveness and Safety in Psoriasis: A Real-Life Experience During the COVID-19 Pandemic. <i>Dermatology and Therapy</i> , 2022, 12, 671-681.	1.4	5
7	Prevalence of Atherosclerosis in Psoriatic Patients Detected with Epiaortic Color Doppler Ultrasound and Computed Tomography Angiography. <i>Dermatology Practical and Conceptual</i> , 2022, 12, e2022011.	0.5	1
8	Moderate-to-severe atopic dermatitis in adolescents treated with dupilumab: A multicentre Italian real-world experience. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1292-1299.	1.3	23
9	Real-life experience on effectiveness and safety of dupilumab in adult patients with moderate-to-severe atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2021, 32, 507-513.	1.1	67
10	Depressive symptoms and insecure attachment predict disability and quality of life in psoriasis independently from disease severity. <i>Archives of Dermatological Research</i> , 2021, 313, 431-437.	1.1	4
11	Dupilumab therapy of atopic dermatitis of the elderly: a multicentre, real-life study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 958-964.	1.3	66
12	A multicenter study on effectiveness and safety of risankizumab in psoriasis: an Italian 16-week real-life experience during the COVID-19 pandemic. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e169-e170.	1.3	31
13	Management of patients with atopic dermatitis undergoing systemic therapy during COVID-19 pandemic in Italy: Data from the DA-COVID-19 registry. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1813-1824.	2.7	28
14	Satisfaction and attitudes toward systemic treatments for psoriasis: A cross-sectional study. <i>Dermatologic Therapy</i> , 2021, 34, e14949.	0.8	4
15	Ixekizumab improves disease severity, clinical symptoms and quality of life in patients with genital psoriasis: A 24-week real-life experience. <i>Dermatologic Therapy</i> , 2021, 34, e14993.	0.8	6
16	Atopic dermatitis in adolescents: Effectiveness and safety of dupilumab in a 16-week real-life experience during the COVID-19 pandemic in Italy. <i>Dermatologic Therapy</i> , 2021, 34, e15035.	0.8	24
17	Treatment of severe psoriasis during pregnancy and breastfeeding: A therapeutic challenging case. <i>International Journal of Women's Dermatology</i> , 2021, 7, 832-834.	1.1	1
18	A case of generalized pustular psoriasis and arthritis treated with ixekizumab. <i>Journal of Dermatological Treatment</i> , 2020, 31, 754-755.	1.1	4

#	ARTICLE	IF	CITATIONS
19	Long-term safety and efficacy of secukinumab in patients with psoriasis and major psychiatric disorders: a case series. <i>Postgraduate Medicine</i> , 2020, 132, 172-175.	0.9	4
20	Certolizumab pegol for the treatment of psoriatic arthritis and plaque psoriasis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 119-128.	1.3	12
21	Disease Severity Is Associated with Alexithymia in Patients with Atopic Dermatitis. <i>Dermatology</i> , 2020, 236, 329-335.	0.9	9
22	Consensus on the place in therapy of TNF- $\alpha$ inhibitors in the treatment of patients with chronic plaque psoriasis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e470-e472.	1.3	6
23	Association between psoriasis and periodontitis, and efficacy of anti-TNF- $\alpha$ therapy. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 508-511.	0.8	2
24	Psoriasis and its management in women of childbearing age: tools to increase awareness in dermatologists and patients. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2020, 155, 434-440.	0.8	7
25	Efficacy and safety of ixekizumab in psoriatic arthritis: a retrospective, single-centre, observational study in a real-life clinical setting. <i>Clinical and Experimental Rheumatology</i> , 2020, 38, 581-582.	0.4	2
26	Omalizumab for chronic spontaneous urticaria in "complex" patients: data from real-life clinical practice. <i>Drug Design, Development and Therapy</i> , 2019, Volume 13, 3181-3186.	2.0	10
27	Apremilast efficacy and safety in a psoriatic arthritis patient affected by HIV and HBV virus infections. <i>Postgraduate Medicine</i> , 2019, 131, 239-240.	0.9	7
28	PsA-Disk, a novel visual instrument to evaluate psoriatic arthritis in psoriatic patients: an Italian derma-rheuma multicentre study. <i>Therapeutic Advances in Chronic Disease</i> , 2019, 10, 204062231984705.	1.1	4
29	Etanercept biosimilar SB4 in the treatment of plaque-type psoriasis and psoriatic arthritis: a single-centre, observational, retrospective, real-life study. <i>British Journal of Dermatology</i> , 2019, 181, 1078-1079.	1.4	10
30	Efficacy and safety of adalimumab after failure of other anti-TNF- $\alpha$ agents for plaque-type psoriasis: clinician behavior in real life clinical practice. <i>Journal of Dermatological Treatment</i> , 2019, 30, 441-445.	1.1	5
31	Rapid, persistent, and simultaneous remission of urticaria and severe atopic dermatitis after treatment with omalizumab. <i>Journal of Dermatological Treatment</i> , 2018, 29, 2-4.	1.1	2
32	Association between Psoriasis and haplotypes of the IgH 3' Regulatory Region 1. <i>Gene</i> , 2018, 669, 47-51.	1.0	6
33	Long-term treatment with etanercept monotherapy in a hemodialyzed patient with moderate-to-severe plaque-type psoriasis and psoriatic arthritis. <i>Giornale Italiano Di Dermatologia E Venereologia</i> , 2018, 153, 882-884.	0.8	2
34	Dose adjustment of biologic therapies for psoriasis in dermatological practice: a retrospective study. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2017, 31, 863-869.	1.3	31
35	Morbid obesity and psoriasis: Disease remission after laparoscopic sleeve gastrectomy. <i>Obesity Research and Clinical Practice</i> , 2017, 11, 370-372.	0.8	4
36	Spotlight on ixekizumab for the treatment of moderate-to-severe plaque psoriasis: design, development, and use in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1643-1651.	2.0	20

#	ARTICLE	IF	CITATIONS
37	Hepatitis B reactivation in psoriasis patients treated with anti-TNF agents: prevention and management. <i>Psoriasis: Targets and Therapy</i> , 2017, Volume 7, 35-40.	1.2	9
38	UVA1 Laser in the Treatment of Vitiligo. <i>Photomedicine and Laser Surgery</i> , 2016, 34, 200-204.	2.1	8
39	Combination therapy with etanercept in psoriasis: Retrospective analysis of efficacy and safety outcomes from real-life practice. <i>Journal of International Medical Research</i> , 2016, 44, 100-105.	0.4	9
40	Influence of body mass index and weight on etanercept efficacy in patients with psoriasis: A retrospective study. <i>Journal of International Medical Research</i> , 2016, 44, 72-75.	0.4	12
41	From patients'™ needs to treatment outcomes in psoriasis: Results from the 'pSORRIDI'™ experience. <i>Journal of International Medical Research</i> , 2016, 44, 95-99.	0.4	5
42	Treatment Adherence to Different Etanercept Regimens, Continuous vs. Intermittent, in Patients Affected by Plaque-Type Psoriasis. <i>Drug Development Research</i> , 2014, 75, S31-S34.	1.4	12
43	Survival rate of antitumour necrosis factor-Î± treatments for psoriasis in routine dermatological practice: a multicentre observational study. <i>British Journal of Dermatology</i> , 2013, 169, 666-672.	1.4	138
44	Frequency of melanocytic nevi in psoriatic patients is related to treatment and not to disease severity. <i>Journal of the American Academy of Dermatology</i> , 2013, 69, 947-953.	0.6	12
45	Efficacy and Safety of Subcutaneous Anti-Tumor Necrosis Factor-Alpha Agents, Etanercept and Adalimumab, in Elderly Patients Affected by Psoriasis and Psoriatic Arthritis: An Observational Long-Term Study. <i>Dermatology</i> , 2012, 225, 312-319.	0.9	68
46	Continuous Treatment of Plaque-Type Psoriasis with Etanercept: An Observational Long-Term Experience. <i>International Journal of Immunopathology and Pharmacology</i> , 2010, 23, 503-509.	1.0	15
47	Long-term experience with etanercept in psoriatic arthritis patients: A 3-year observational study. <i>Journal of Dermatological Treatment</i> , 2009, 20, 354-358.	1.1	9
48	Efficacy and Safety of Etanercept in Psoriasis after Switching from Other Treatments. <i>American Journal of Clinical Dermatology</i> , 2009, 10, 319-324.	3.3	69
49	Influence and Variation of the Body Mass Index in Patients Treated with Etanercept for Plaque-Type Psoriasis. <i>International Journal of Immunopathology and Pharmacology</i> , 2009, 22, 219-225.	1.0	41
50	Increased Frequency of Ig Heavy-Chain HS1,2-A Enhancer *2 Allele in Dermatitis Herpetiformis, Plaque Psoriasis, and Psoriatic Arthritis. <i>Journal of Investigative Dermatology</i> , 2008, 128, 1920-1924.	0.3	34
51	Etanercept at Different Dosages in the Treatment of Generalized Pustular Psoriasis: A Case Series. <i>Dermatology</i> , 2008, 216, 355-360.	0.9	36
52	Clobetasol propionate foam 0.05% as a novel topical formulation for plaque-type and scalp psoriasis. <i>Journal of Dermatological Treatment</i> , 2007, 18, 84-87.	1.1	35
53	An Italian Study on Psoriasis and Depression. <i>Dermatology</i> , 2006, 212, 123-127.	0.9	210
54	Treatment of erythrodermic psoriasis with etanercept. <i>British Journal of Dermatology</i> , 2006, 155, 156-159.	1.4	49

#	ARTICLE	IF	CITATIONS
55	High-dose initiation of etanercept in psoriatic arthritis and plaque psoriasis: Efficacy, safety and impact on patients' quality of life. <i>Journal of Dermatological Treatment</i> , 2006, 17, 355-358.	1.1	15
56	Treatment of vitiligo with the 308 nm excimer laser. <i>Clinical and Experimental Dermatology</i> , 2004, 29, 133-137.	0.6	69